Sign In
Buy BIIB
$195.96
+7.13 (+3.78%)
At Close: Jun 03, 2026
Biogen and Belgian partner UCB announce positive data from late-stage trial of lupus treatment
07:18am, Tuesday, 24'th Sep 2024
Biogen Inc.'s stock rose 2% early Tuesday, after the company and Belgian partner UCB announced positive results in a late-stage trial
Biogen-UCB's lupus drug meets main goal of late-stage trial
01:04am, Tuesday, 24'th Sep 2024
Biogen and Belgian partner UCB said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in patients with the chronic disease, a surprise result after the drug failed
BRUSSELS and CAMBRIDGE, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today announced positive topline results from the Phase 3 PHOENYCS GO stud
Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ™
08:00am, Friday, 20'th Sep 2024
INCHEON, South Korea and CAMBRIDGE, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European Medicines Agency's (EMA) Commit
Biogen Inc. (BIIB) Cantor Fitzgerald Global Healthcare Conference (Transcript)
03:36pm, Wednesday, 18'th Sep 2024
Biogen Inc. (NASDAQ:BIIB ) Cantor Fitzgerald Global Healthcare Conference Call September 18, 2024 1:20 PM ET Company Participants Chuck Triano - Head, Investor Relations Conference Call Participants E
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
10:47am, Monday, 16'th Sep 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Despite favorable views on litifilimab, AbbVie's Rinvoq and BMS' Sotyktu capture the most prescriber interest for approval, according to Spherix Global Insights. Despite favorable views on litifilimab
Healthcare Stocks Have Popped. Consider These 2 That Haven't.
03:32pm, Thursday, 12'th Sep 2024
Money has poured into the sector as markets have grown concerned about the economy.
Biogen Board Appoints Two New Independent Directors
07:30am, Thursday, 12'th Sep 2024
Dr. Lloyd Minor and Prof Sir Menelas Pangalos bring significant scientific expertise and considerable experience in medicine research and development Dr. Lloyd Minor and Prof Sir Menelas Pangalos brin
Comparable clinical efficacy and safety in Treatment Period 2 (TP2, Week 24-48) is maintained after switch from reference tocilizumab to TOFIDENCE (BAT1806/BIIB800) Phase 3 clinical data in totality
Alzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatment
08:00am, Sunday, 08'th Sep 2024
Leqembi, an Alzheimer's drug from Biogen and Eisai, could give patients at the earliest stages of the disease more time to live normally and independent of others. But patients face a long road to tre
Biogen's Phase II/III SMA Study for Higher Spinraza Dose Meets Goals
12:00pm, Thursday, 05'th Sep 2024
BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.
Biogen Inc.'s (BIIB) Morgan Stanley's 22nd Annual Global Healthcare Conference Transcript
01:57pm, Wednesday, 04'th Sep 2024
Biogen Inc. (NASDAQ:BIIB ) Morgan Stanley's 22nd Annual Global Healthcare Conference September 4, 2022 10:00 AM ET Company Participants Mike McDonnell – Chief Financial Officer Priya Singhal – Exe
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
07:30am, Wednesday, 04'th Sep 2024
CAMBRIDGE, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced positive, topline data from the pivotal cohort (Part B) of the Phase 2/3 DEVOTE study evaluating the saf
Biogen Stock Declines 20.9% Year to Date: Time to Sell?
11:10am, Tuesday, 03'rd Sep 2024
BIIB's reasonable valuation, an improving pipeline and better sales prospects of new drugs are good enough reasons to stay invested for now.
